Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102958
Revised: January 18, 2025
Accepted: February 24, 2025
Published online: April 24, 2025
Processing time: 143 Days and 15.3 Hours
Highly expressed in the gastrointestinal mucosa, huntingtin-associated protein 1 (HAP1) is closely associated with tumor development and prognosis.
To investigate the clinical utility of HAP1 expression in gastric cancer (GC).
We randomly selected 124 GC patients had not undergone preoperative radio
HAP1 protein and mRNA levels were lower in fresh GC tissues than in normal mucosal tissues (P < 0.001, respectively). Immunohistochemistry also revealed lower HAP1 expression in GC tissues and metastatic lymph nodes than in normal mucosal tissues (P < 0.05). HAP1 expression in GC was closely associated with differentiation, lymph node metastasis, lymph node ratio, remote metastasis, clinical stage, tumor location, and survival time (P < 0.05). Furthermore, HAP1 expression independently predicted GC (P < 0.05) and was more accurate in advanced GC than in early GC (P < 0.05).
HAP1 is an important prognostic biomarker for GC, with low HAP1 expression positively correlating with poor overall survival, especially in advanced clinical stages.
Core Tip: The clinical utility of huntingtin-associated protein 1 (HAP1) expression in gastric cancer (GC) was assessed. HAP1 expression was significantly lower in GC tissues than in normal gastric mucosa, and was strongly associated with GC progression and metastasis. Downregulation of HAP1 correlates with poor overall survival in patients with GC, especially in advanced clinical stages. Thus, HAP1 is a promising prognostic marker for GC, with important implications for advancing treatment.